BioCryst Pharmaceuticals, Inc. (BCRX)

Several events impacted BioCryst Pharmaceuticals' stock price in the past six months. BioCryst shares closed higher after completing the acquisition of Astria Therapeutics. Analysts maintained a "Moderate Buy" consensus rating despite recent earnings pressures. Royal Bank of Canada lowered its price target for BCRX to $13 from $14, while still maintaining an outperform rating. The company finalized the acquisition of Astria Therapeutics. The FDA approved an oral pellet formulation of ORLADEYO for pediatric HAE patients. BioCryst announced its Q3 2025 earnings, missing estimates but raised its ORLADEYO revenue guidance for the full year 2025 and fully repaid its term debt. BioCryst announced the proposed acquisition of Astria Therapeutics. The company completed the sale of its European business. BioCryst secured a contract from the U.S. Department of Health and Human Services for the procurement of RAPIVAB to treat influenza. The Q2 2025 earnings call highlighted strong ORLADEYO revenue growth.

Demand for RAPIVAB is higher during flu seasons. For ORLADEYO, patient demand is generally more stable due to the chronic nature of HAE, but the company has noted "seasonal payment dynamics" that can affect Q1 revenue.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare and serious diseases. The company operates in the biotechnology and medical research sector, with a focus on improving the lives of individuals with hereditary angioedema (HAE) and other complement-mediated and rare diseases. Its major products include ORLADEYO (berotralstat), RAPIVAB (peramivir injection), BCX10013, BCX17725, Navenibart, Avoralstat and STAR-0310.

BioCryst Pharmaceuticals is headquartered in Durham, North Carolina, with its Discovery Center of Excellence in Birmingham, Alabama. The company has a global presence, with ORLADEYO approved in over 45 countries and RAPIVAB approved in the United States, Japan, Korea, and China. BioCryst has also filed applications for ORLADEYO oral pellets in pediatric patients with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency, with additional regulatory filings planned in other global territories, including Canada.

BioCryst Pharmaceuticals has generally maintained a positive outlook from analysts, with a consensus "Buy" rating. ORLADEYO has shown strong and durable patient demand, contributing to significant revenue growth. The company's strategic acquisitions, such as Astria Therapeutics, are seen as enhancing its market position in rare disease treatments. However, Jim Cramer advised investors to "just stay away" from BioCryst Pharmaceuticals. The company's Q3 2025 earnings missed analyst expectations for both EPS and revenue, which contributed to some stock pressure.

Institutional investors hold a significant portion of BioCryst Pharmaceuticals' stock, ranging from approximately 92.45% to 92.91%. Individual investors hold approximately 2.02% to 3.48% of the company's stock.